Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS -mutant multiple myeloma | BMC Cancer | Full Text

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS -mutant multiple myeloma | BMC Cancer | Full Text

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MA...

Authors:Priya Sriskandarajah, Alexis De Haven Brandon, Kenneth MacLeod, Neil O. Carragher, Vladimir Kirkin, Martin Kaiser and Steven R. Whittaker

Citation:BMC Cancer 2020 20:269

Content type:Research article

Published on: 30 March 2020

• ViewFull Text
 
• ViewPDF